Table 3.
Review of literature on transarterial radioembolization (TARE) of neuroendocrine tumor liver metastases.
| Author | Year | N | PNET (N) | Rx | Sx Resp (%) | Imaging | Median PFS (mo) | Median OS (mo) | One-year Survival (%) | Five-Year Survival (%) | 30-Day Morbidity (mo) | 30-Day Mortality (mo) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CR+PR (%) | SD (%) | PD (%) | ||||||||||||
| Rhee [67] | 2008 | 22 | 7 | TARE Glass | - | 54 | 38 | 8 | - | 22 | - | - | - | 5 ¥ |
| 20 | 4 | TARE Resin | - | 50 | 44 | 6 | - | 28 | - | - | - | - | ||
| Kennedy [66] | 2008 | 148 | 28 | TARE | - | 63 | 23 | 5 | - | 70 | - | - | 33 | - |
| Cao [65] | 2010 | 51 | 14 | TARE | - | 39 | 27 | 33 | - | 36 | - | - | - | 2 |
| Memon [68] | 2012 | 40 | 9 | TARE | 84 | 64 | 33 | 4 | - | 34 | 73 | - | - | - |
| Paprottka [69] | 2012 | 42 | 9 | TARE | 95 | 23 | 75 | 3 | - | - | - | - | - | - |
| Gebhard [70] | 2013 | 17 | unk | TARE | - | - | - | - | - | - | 68 | 12 | - | |
| 29 | TAE | - | - | - | - | - | - | 82 | 3 | - | ||||
| Chen [51] | 2017 | 50 | 23 | TACE | - | - | - | - | 8 | 33 | 82 | - | - | - |
| 64 | 26 | TARE | - | - | - | - | 16 | 48 | 79 | - | - | - | ||
| 41 | 22 | TAE | - | - | - | - | 15 | - | 90 | - | - | - | ||
| Do Minh [71] | 2017 | 122 | 44 | cTACE | - | 3 | 92 | 4 | - | 34 | 81 | 28 | 85 | - |
| 26 | 10 | DEB-TACE | - | 4 | 92 | 4 | - | 22 | 73 | 10 | 89 | - | ||
| 44 | 13 | TARE | - | 0 | 89 | 11 | - | 24 | 71 | 19 | 84 | - | ||
| Tomozawa [72] | 2018 | 93 | 27 | TARE | - | 25 | 67 | 8 | - | - | - | - | - | - |
| Egger [73] | 2020 | 51 | 16 | TARE | - | 24 | 59 | 17 | 16 | 36 | - | 35 | 14 | 2 |
| 197 | 46 | TACE | - | 30 | 66 | 4 | 20 | 50 | - | 42 | 23 | 3 | ||
¥ for entire cohort; N, number of patients; Rx, treatment; Sx Resp, symptom response; TAE, transarterial embolization; TACE, transarterial chemoembolization; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression free survival; OS, overall survival; mo, months; yr, year; PNET, pancreatic neuroendocrine tumor; unk, unknown.